A new supersulfated low-molecular-weight heparin (MW 3500; SD
4.0 - 4.4) (SS-LMW-H) has been prepared.
This SS-LMW-H does not interact with Antithrombin III.
Clinical advantages:
(i) potent antithrombotic drug
(ii) useful in clinical situations with genetical or secondary
ATIII deficiency
(iii) antiatherosclerotic drug
(iv) pro-fibrinolytic drug
(v) a drug inhibiting the hyperplasia after a vascular damage and
therefore an inhibitor of coronary restenosis after an angiplasty
procedure.
Looking for a partner for the commercialization of the product.
Contact: Pier Carlo Montecucchi at MonteGen
Email: innovations at montegen.com
<www.montegen.com>
Tel: 1-212-208-2647
Fax: 1-212-208-2648
--
